Group B streptococcal infection historical perspective

Revision as of 18:22, 19 August 2014 by Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{Group B streptococcal infection}} {{CMG}}; {{AE}} {{Rim}} ==Overview== In the 1970s, the bacterium group B Streptococcus (GBS) emerged as the leading infectious c...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Group B Streptococcal Infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Group B Streptococcal Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Group B streptococcal infection historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Group B streptococcal infection historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Group B streptococcal infection historical perspective

CDC on Group B streptococcal infection historical perspective

Group B streptococcal infection historical perspective in the news

Blogs on Group B streptococcal infection historical perspective

Directions to Hospitals Treating Group B streptococcal infection

Risk calculators and risk factors for Group B streptococcal infection historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

In the 1970s, the bacterium group B Streptococcus (GBS) emerged as the leading infectious cause of early neonatal morbidity and mortality in the United States.[1][2][3][4] Beginning in the mid 1980s, clinical trials and well-designed observational studies demonstrated that administering intravenous antibiotics during labor to women at risk for transmitting GBS to their newborns could prevent invasive disease in the first week of life (i.e., early-onset disease).[5][6][7][8][9] As a result of the collaborative efforts of clinicians, researchers, professional organizations, parent advocacy groups, and the public health community in the 1990s, recommendations for intrapartum prophylaxis to prevent perinatal GBS disease were issued in 1996 by the American College of Obstetricians and Gynecologists (ACOG)[10] and CDC[11] and in 1997 by the American Academy of Pediatrics (AAP).[12] Revised guidelines for the prevention of early-onset GBS disease issued in 2002 recommended universal culture-based screening of all pregnant women at 35--37 weeks' gestation to optimize the identification of women who should receive intrapartum antibiotic prophylaxis[13]. The most recent CDC guidelines were published in 2010. [14]

References

  1. Chattopadhyay B (1975). "Fatal neonatal meningitis due to group B streptococci". Postgrad Med J. 51 (594): 240–3. PMC 2495958. PMID 1105496.
  2. McCracken GH (1973). "Group B streptococci: the new challenge in neonatal infections". J Pediatr. 82 (4): 703–6. PMID 4572746.
  3. Franciosi RA, Knostman JD, Zimmerman RA (1973). "Group B streptococcal neonatal and infant infections". J Pediatr. 82 (4): 707–18. PMID 4572747.
  4. Barton LL, Feigin RD, Lins R (1973). "Group B beta hemolytic streptococcal meningitis in infants". J Pediatr. 82 (4): 719–23. PMID 4572748.
  5. Allardice JG, Baskett TF, Seshia MM, Bowman N, Malazdrewicz R (1982). "Perinatal group B streptococcal colonization and infection". Am J Obstet Gynecol. 142 (6 Pt 1): 617–20. PMID 7039316.
  6. Boyer KM, Gotoff SP (1986). "Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis". N Engl J Med. 314 (26): 1665–9. doi:10.1056/NEJM198606263142603. PMID 3520319.
  7. Lim DV, Morales WJ, Walsh AF, Kazanis D (1986). "Reduction of morbidity and mortality rates for neonatal group B streptococcal disease through early diagnosis and chemoprophylaxis". J Clin Microbiol. 23 (3): 489–92. PMC 268680. PMID 3514659.
  8. Tuppurainen N, Hallman M (1989). "Prevention of neonatal group B streptococcal disease: intrapartum detection and chemoprophylaxis of heavily colonized parturients". Obstet Gynecol. 73 (4): 583–7. PMID 2494620.
  9. Garland SM, Fliegner JR (1991). "Group B streptococcus (GBS) and neonatal infections: the case for intrapartum chemoprophylaxis". Aust N Z J Obstet Gynaecol. 31 (2): 119–22. PMID 1930031.
  10. American College of Obstetricians and Gynecologists. ACOG committee opinion. Prevention of early-onset group B streptococcal disease in newborns. Number 173,June 1996. Committee on Obstetric Practice. American College of Obstetrics and Gynecologists. Int J Gynaecol Obstet 1996;54:197--205.
  11. CDC. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR 1996;45(No. RR-7).
  12. American Academy of Pediatrics. Revised guidelines for prevention of early-onset group B streptococcal (GBS) infection. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics 1997;99:489--96.
  13. CDC. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR 2002;51(No. RR-11).
  14. Verani J.R., McGee L, and Schrag S.J. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010.CDC.gov

Template:Bacterial diseases


Template:WikiDoc Sources